“…In recent years, rapid developments in the field of nanotechnology have fueled the evolution of nanomedicine for cancer therapy. ,, As recognized, nanomaterial/nanoparticle-based systems provide an opportunity for multimodal and site-specific delivery of therapeutics to target tissues with improved pharmacokinetics and stability, reduced nonspecificity, and enhanced permeability and retention. ,,, As a matter of fact, neoplastic diseases, especially disseminated hematological malignancies (such as lymphoma, leukemia, and multiple myeloma), can benefit immensely from the broad panorama of nanoparticles providing innovative noninvasive approaches for diagnostics, treatment, and theranostics. ,− Among a plethora of functionalized nanomaterials (carbon nanotubes, inorganic mesoporous silica, quantum dots, peptide nanostructures, liposomes, polymeric nanoparticles, etc. ) , used in drug delivery, disease diagnostics, and therapy, gold-based nanoparticles display excellent efficacy as drug carriers, photothermal agents, contrast agents, and radiosensitizers, ,, owing to their versatility with regard to chemical modifications, high biocompatibility, and strong localized surface plasmon resonance (LSPR). ,, Porous gold nanoframeworks (AuNFs) with a large interior surface present a unique opportunity to easily accommodate therapeutic molecules within the well-defined mesopores and then, in contrast to more rapidly degradable polymeric nanocarriers, delay their elimination by the kidney or liver for a prolonged therapeutic period.…”